Form 4: DURECT CMO Sells Shares, Options Post-Bausch Health Merger

DURECT's Chief Medical Officer, Norman Sussman, disposed of all common stock and certain stock options following the company's acquisition by Bausch Health Americas, Inc.

Summary

• DURECT Corporation was acquired by Bausch Health Americas, Inc. through a tender offer and subsequent merger, effective September 11, 2025.
• Shareholders received $1.75 per share in cash plus one non-tradeable contingent value right (CVR).
• The CVR entitles holders to a pro rata portion of up to $350,000,000 in aggregate milestone payments, contingent on specific achievements.
• Norman Sussman, Chief Medical Officer, disposed of 46,425 shares of common stock.
• Stock options with an exercise price less than $1.75 were accelerated, exercised, and the resulting shares were tendered in the merger.
• Stock options with an exercise price equal to or greater than $1.75 were canceled, and holders became eligible for a cash retention bonus tied to net sales milestones.
• Sussman's options with exercise prices of $17.70, $20.30, $8.71, and $5.07 were canceled.
• Sussman's options with an exercise price of $1.30 were likely exercised and tendered as part of the merger.

Sentiment

Score: 7

Explanation: The filing details the completion of a merger, which provides a clear exit for shareholders and a structured path for option holders. The inclusion of CVRs offers potential upside, while retention bonuses aim to secure key talent. This is a definitive event with structured outcomes, generally positive for the company's transition into a larger entity.

Positives

• DURECT shareholders received a cash consideration of $1.75 per share.
• Shareholders also received contingent value rights (CVRs) offering potential future payments up to $350,000,000 based on milestone achievements.
• Certain stock options with exercise prices below the cash consideration were accelerated, allowing holders to participate in the tender offer.
• Holders of canceled out-of-the-money options are eligible for a cash retention bonus tied to net sales milestones, providing a potential future incentive.

Negatives

• Norman Sussman disposed of all his common stock holdings (46,425 shares) in DURECT.
• Stock options with exercise prices equal to or greater than the $1.75 cash amount were canceled, meaning they lost their direct equity value.
• The contingent value rights are non-tradeable, limiting liquidity for that portion of the consideration.

Risks

• The contingent value rights (CVRs) are subject to the achievement of specified milestones, meaning the full $350,000,000 aggregate payment is not guaranteed.
• The cash retention bonuses for canceled options are also subject to the achievement of certain net sales milestones, introducing uncertainty regarding their payout.

Future Outlook

DURECT Corporation will continue as a wholly owned subsidiary of Bausch Health Americas, Inc. Future potential payments to former shareholders and option holders are tied to the achievement of specific milestones related to the acquired company's performance.

Management Comments

• Tendering stockholders received a consideration of $1.75 per share, net to the seller of such shares in cash, without interest thereon and less any applicable withholding taxes (the 'Cash Amount'), plus one non-tradeable contingent value right per share...
• At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger.
• Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors.

Industry Context

This transaction reflects a trend of larger pharmaceutical or healthcare companies acquiring smaller biotech firms, often to gain access to specific drug pipelines, technologies, or market segments. The use of contingent value rights (CVRs) is a common mechanism in such acquisitions to bridge valuation gaps and incentivize post-merger performance, particularly for assets still in development or early commercialization.

Comparison to Industry Standards

• The use of a tender offer followed by a merger is a standard acquisition structure in the industry.
• The inclusion of Contingent Value Rights (CVRs) is a common practice in biotech/pharma acquisitions, similar to the acquisition of Acceleron Pharma by Merck or The Medicines Company by Novartis, where CVRs were used to provide additional value tied to clinical or regulatory milestones.
• The retention plan for option holders, tied to net sales milestones, is a typical strategy to retain key talent post-acquisition and align their incentives with the acquiring company's goals for the acquired assets.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $1.75 cash per share and CVRs, providing immediate liquidity and potential future upside.
• Employees (specifically option holders): Those with in-the-money options had them accelerated and could tender shares; those with out-of-the-money options had them canceled but are eligible for retention bonuses, aiming to retain key talent.
• DURECT Corporation: Becomes a wholly owned subsidiary of Bausch Health Americas, Inc., integrating into a larger corporate structure.
• Bausch Health Americas, Inc.: Successfully acquired DURECT, expanding its portfolio.

Next Steps

• Achievement of specified milestones for contingent value rights to trigger payments to former shareholders.
• Achievement of certain net sales milestones for canceled option holders to receive cash retention bonuses.

Key Dates

Keywords

DURECT, DRRX, Bausch Health, Merger, Acquisition, Tender Offer, Form 4, Norman Sussman, Chief Medical Officer, Stock Options, Contingent Value Rights, CVR, Share Disposal, Executive Compensation